Bausch + Lomb Q3 revenue $1.196B (+19% YoY); raises FY2024 revenue guidance

Bausch & Lomb Corp

2024-Q3 EPS reported -$0.89 revenue$3,511,000,000

GAAP net income $4M vs net loss of $84M YoY; adjusted EPS $0.13 ($0.17 ex-IPR&D).
Adjusted EBITDA $212M ($227M ex-IPR&D) vs $187M YoY, driven by broad-based sales growth.
Pharmaceuticals revenue surged 76% to $306M on XIIDRA acquisition and MIEBO launch.
FY2024 revenue guidance raised to $4.725-4.825B (prior $4.70-4.80B); adjusted EBITDA outlook unchanged.
Cash flow from operations $154M, up from $48M YoY, aided by gross profit and working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.